RxDoctor Payments Data

Timothy Williams, DO

Family Medicine · Knoxville, TNNPI 1174939789

Payments from drug & device makers

$10,540in general payments, 2019–2025

Across 717 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AbbVie$1K
  • Lilly USA, LLC$925
  • GSK$921
  • Novo Nordisk$866
  • Amgen$610
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,540100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,540 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$238,894
Medicare patients
421
Services billed
6,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$103,428
MounjaroTirzepatide92$95,319
OzempicSemaglutide57$75,686
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$73,929
XareltoRivaroxaban62$59,148
Tresiba Flextouch U-200Insulin Degludec24$57,383
TrulicityDulaglutide32$30,433
JardianceEmpagliflozin26$19,496
RybelsusSemaglutide16$12,726
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,774
Fiasp FlextouchInsulin Aspart (Niacinamide)20$8,034
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,196
Breo ElliptaFluticasone/Vilanterol11$4,409
PremarinEstrogens, Conjugated14$4,099
Atorvastatin Calcium443$3,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$925$125,752124 claims
PfizerEliquis, Premarin, Paxlovid$1,808$110,386162 claims
Novo NordiskOzempic, Rybelsus$866$88,41273 claims
GSKTrelegy Ellipta, Breo Ellipta$921$78,33882 claims
Johnson & JohnsonXarelto$169$59,14862 claims
Boehringer IngelheimJardiance$440$19,49626 claims
AbbVieSynthroid$1,200$2,42032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →